Humana (NYSE:HUM) Upgraded to “Outperform” at Royal Bank Of Canada

Humana (NYSE:HUM – Get Free Report) was upgraded by equities research analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage currently has a $563.00 target price on the insurance provider’s stock, up from their previous target price of $415.00. Royal Bank Of Canada‘s price objective indicates a potential upside of 25.01% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Wells Fargo & Company raised their target price on shares of Humana from $502.00 to $602.00 and gave the company an “overweight” rating in a research report on Thursday. Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price target for the company in a research report on Wednesday, July 29th. Deutsche Bank initiated coverage on shares of Humana in a research note on Thursday, July 30th. They set a “hold” rating on the stock. Leerink Partners raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price objective on the stock in a report on Thursday, July 30th. Finally, Guggenheim lifted their price objective on shares of Humana from $471.00 to $521.00 and gave the company a “buy” rating in a report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $482.96.

View Our Latest Stock Analysis on HUM

Humana Stock Performance

Shares of Humana stock opened at $450.38 on Monday. The firm has a market cap of $54.09 billion, a P/E ratio of 43.81, a P/E/G ratio of 2.14 and a beta of 0.65. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.61. Humana has a 12 month low of $163.11 and a 12 month high of $456.50. The stock’s fifty day moving average price is $408.53 and its 200-day moving average price is $316.91.

Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same period in the previous year, the company posted $3.24 earnings per share. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities research analysts expect that Humana will post 9.66 earnings per share for the current fiscal year.

Insider Transactions at Humana

In other Humana news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the transaction, the insider owned 21,910 shares in the company, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is owned by company insiders.

Institutional Trading of Humana

Hedge funds have recently modified their holdings of the company. Johnson Financial Group Inc. bought a new stake in shares of Humana in the 2nd quarter valued at about $26,000. Trust Co. of Vermont bought a new position in shares of Humana during the 2nd quarter worth approximately $28,000. Bogart Wealth LLC raised its stake in shares of Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after acquiring an additional 48 shares in the last quarter. MidFirst Bank bought a new position in shares of Humana during the 2nd quarter worth approximately $35,000. Finally, Highland Investment Advisors LLC purchased a new stake in Humana during the second quarter valued at approximately $43,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

(Get Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

See Also

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.